A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed

Overview

The purpose of this study is to evaluate the steady state pharmacokinetics (PK) of rilpivirine (RPV) and determine the appropriate dose of RPV in combination with other antiretrovirals (ARVs) in participants aged greater than or equal to 2 to less than 12 years and to evaluate the safety and tolerability of RPV in combination with other ARVs in participants of same age group over a 48-week treatment period with primary endpoint at Week 24.

Full Title of Study: “A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 9, 2023

Detailed Description

Participants infected with human immunodeficiency virus type 1 (HIV-1) are routinely treated with combinations of multiple drugs which reduces HIV-1 ribonucleic acid (RNA) to undetectable levels in a substantial proportion of participants and counteracts the risk of viral resistance development. RPV is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with in vitro activity against wild type (WT) HIV-1 and against NNRTI-resistant HIV-1 mutants. A medical need still exists for the development of age/weight appropriate formulations in children less than (<) 12 years of age. In this study, participants will switch to RPV plus other ARVs. The primary analysis will be performed at Week 24. A participant will be considered to have completed the study if he or she has completed assessments at Week 48 of the study intervention phase. The total study duration for each participant, including screening and study intervention phases, will be approximately 54 weeks. Key efficacy assessments include determination of plasma HIV-1 RNA viral load and measurement of CD4+ cell count. Key safety assessments will include the monitoring of (serious) adverse events ([S]AEs) and HIV-related events, clinical laboratory tests, cardiovascular safety monitoring (vital signs and 12 lead electrocardiogram [ECGs]), and physical examination (including growth).

Interventions

  • Drug: Rilpivirine
    • Rilpivirine 25 mg tablets for the 25 mg daily dose, or tablets for or a weight-adjusted dose. Administered orally once daily.
  • Drug: ARV Background Regimen
    • The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine [AZT], abacavir [ABC], tenofovir alafenamide [TAF], or tenofovir disoproxil fumarate [TDF] in combination with emtricitabine [FTC] or lamivudine [3TC]), whichever are approved and marketed or considered local standard of care for children aged between 2 and < 12 years in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir [DTG] or raltegravir) can also be administered in combination with RPV, as appropriate.

Arms, Groups and Cohorts

  • Experimental: Rilpivirine (RPV) (25 mg or adjusted weight-based dose)
    • Participants will receive rilpivirine (RPV 25 milligram [mg], adjusted weight-based dose) orally once daily in combination with an investigator selected background regimen (that is investigator-selected antiretrovirals [ARVs] such as nucleoside/nucleotide reverse transcriptase inhibitor [N{t}RTIs] and integrase inhibitors) for 48 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Area Under the Plasma Concentration-time Curve from Time of Administration up to 24 Hours Postdose (AUC[24h]) of Rilpivirine (RPV)
    • Time Frame: Up to 24 hours postdose
    • AUC(24h) is area under the plasma concentration-time curve from time of administration to 24 hours postdose, calculated by linear-linear trapezoidal summation or population pharmacokinetic (PK) analysis.
  • Percentage of Participants with Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Week 24
    • Time Frame: Up to Week 24
    • Percentage of participants with Grade 3 and 4 AEs will be assessed on Division of AIDS (DAIDS) grading table where Grade 3: Severe and Grade 4: Potentially Life-threatening. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE deemed medically important, or is a suspected transmission of any infectious agent via a medicinal product, or is an AE resulting in any of the following outcomes: death, is life-threatening.
  • Percentage of Participants with Human Immunodeficiency Virus (HIV)-Related Events
    • Time Frame: Up to Week 24
    • Percentage of participants with HIV-related events HIV-related events (including acquired immune deficiency syndrome [AIDS]-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection) through 24 weeks of study treatment will be reported.
  • Percentage of Participants Experiencing Premature Discontinuation due to AEs Through Week 24
    • Time Frame: Up to Week 24
    • Percentage of participants who prematurely discontinued study due to AEs will be reported.

Secondary Measures

  • Percentage of Participants with AEs/Human Immunodeficiency Virus (HIV)-related Events Through 24 and 48 Weeks
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with AEs/HIV-related events through 24 and 48 weeks of study treatment will be reported.
  • Severity of AEs/HIV-related Events Through 24 and 48 Weeks of Study Treatment
    • Time Frame: Up to 24 and 48 weeks
    • Severity of AEs/HIV-related events will be assessed based on DAIDS grading table where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Potentially Life-threatening.
  • Percentage of Participants with Abnormalities in Clinically Laboratory Parameters
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with abnormalities in Clinically Laboratory results will be reported.
  • Percentage of Participants with Abnormalities in Electrocardiogram (ECG)
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with abnormalities in ECG will be reported.
  • Percentage of Participants with Abnormalities in Vital Signs
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with abnormalities in vital signs will be reported.
  • Percentage of Participants with Abnormalitie in Physical Examination
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with abnormalitie in physical examination will be reported.
  • Percentage of Participants with HIV-1 Ribonucleic Acid (RNA) <50 and >=50 Copies/mL Through 24 and 48 Weeks
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants having viral load (plasma HIV-1 RNA levels) less than (<) 50 copies/milliliter (mL) and >=50 copies/mL measured by the Food and Drug Administration (FDA) snapshot algorithm will be reported. The FDA snapshot analysis is based on the last observed plasma viral load data within the visit window (that is, Weeks 24 and 48).
  • Percentage of Participants with HIV-1 Ribonucleic Acid (RNA) <400 and >=400 Copies/mL Through 24 and 48 Weeks
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants having viral load (plasma HIV-1 RNA levels) less than (<) 400 copies/milliliter (mL) and >=400 copies/mL measured by the Food and Drug Administration (FDA) snapshot algorithm will be reported. The FDA snapshot analysis is based on the last observed plasma viral load data within the visit window (that is, Weeks 24 and 48).
  • Cluster Differentiation 4 (CD4+) Cell Count Through 24 and 48 Weeks
    • Time Frame: Up to 24 and 48 weeks
    • CD4+ cell count for immunologic changes will be determined through Weeks 24 and 48.
  • Predose Plasma Concentration (C0h) of RPV
    • Time Frame: Predose
    • C0h is defined as the predose plasma concentration or concentration just prior to study drug administration (observed and through population PK analysis).
  • Maximum Observed Plasma Concentration (Cmax) of RPV
    • Time Frame: Predose, 2, 4, 5, 6, 9, 12, 24 hours postdose
    • Cmax is the maximum observed plasma concentration.
  • Percentage of Participants with Virologic Failure
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with virologic failure (that is, HIV 1 RNA >=50 and >=400 copies/mL) per Snapshot approach will be reported.
  • Percentage of Participants with Treatment Adherence Based on Tablet Count Through 24 and 48 Weeks
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with treatment adherence as assessed by tablet count (study intervention accountability) through 24 and 48 weeks of study treatment will be reported.
  • Percentage of Participants with Treatment Adherence as Assessed by PENTA Adherence Questionnaire Through 24 and 48 Weeks
    • Time Frame: Up to 24 and 48 weeks
    • Percentage of participants with treatment adherence as assessed by the Pediatric European Network for the Treatment of AIDS (PENTA) adherence questionnaire through 24 and 48 weeks of study treatment will be reported. The responses to the PENTA adherence questionnaire will be tabulated at each time point. Treatment adherence will be further summarized per time point based on a “worst case” combination of results for a number of sponsor-selected questions, categorizing participants into “treatment adherent” and “treatment non-adherent”.

Participating in This Clinical Trial

Inclusion Criteria

  • Weighing at least 11 kilogram (kg) at screening – Have documented chronic Human Immunodeficiency Virus (HIV-1) infection – On a stable antiretroviral (ARV) regimen for at least 6 months prior to screening and virologically suppressed with documented evidence of at least 2 plasma viral loads less than (<) 50 HIV-1 ribonucleic acid (RNA) copies/milliliter (mL): one within 2-12 months prior to screening and one at screening – Can switch from any ARV class – Never been treated with a therapeutic HIV vaccine – Historical HIV-1 genotyping result at screening for children aged >=2 to <6 years (and for children aged >=6 to <12 years if a historical HIV-1 genotyping result is available at screening) must demonstrate sensitivity to RPV and to the selected background ARVs Exclusion Criteria:

  • Have previously documented HIV-2 infection – Have known or suspected acute (primary) HIV-1 infection – Taken any disallowed concomitant therapies within 4 weeks before the planned first dose of study intervention – Any current or history of adrenal disorder – A history of virologic failure to ARVs with or without availability of an HIV-1 genotype result at the time of failure

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: 11 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Janssen Research & Development, LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Janssen Research & Development, LLC Clinical Trial, Study Director, Janssen Research & Development, LLC
  • Overall Contact(s)
    • Study Contact, 844-434-4210, JNJ.CT@sylogent.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.